These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 4085523)

  • 1. Human pharmacokinetics of cadralazine: a new vasodilator.
    Hauffe SA; Dubois JP; Imhof PR
    Eur J Drug Metab Pharmacokinet; 1985; 10(3):217-23. PubMed ID: 4085523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition and pharmacokinetics of cadralazine and individual metabolites in man.
    Schütz H; Faigle JW; Küng W; Theobald W
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):147-53. PubMed ID: 4043143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of an active cadralazine metabolite in plasma and blood vessels of spontaneously hypertensive rats.
    Terauchi Y; Watari S; Ishikawa S; Takeyama K; Sekine Y; Hashimoto M; Hayashi T
    Arzneimittelforschung; 1988 Feb; 38(2):237-9. PubMed ID: 3370071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily.
    Marichal JF; Brunel P; Lecaillon JB; Godbillon J; Faller B; Brignon P; Ménard J
    Eur J Drug Metab Pharmacokinet; 1992; 17(3):213-20. PubMed ID: 1490491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cadralazine in a large group of hypertensive patients chronically treated with cadralazine: advantage over a conventional study in a small group of patients.
    Lecaillon JB; Dubois JP; Darragon T; Motolese M; Racine A; Ducret F; Grouberman D; Cordonnier D; Chanard J; Glorioso M
    Ther Drug Monit; 1991 Mar; 13(2):103-8. PubMed ID: 2053115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and bioavailability of bemoradan, a long-acting inodilator in healthy males.
    Huang SM; Brusser L; Chien SC; Simon D; Smith IL; Abrams LS; Lasseter K
    Int J Clin Pharmacol Ther; 1994 Feb; 32(2):62-4. PubMed ID: 8004360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of cadralazine in human plasma and urine by high-performance liquid chromatography.
    Hauffe SA; Dubois JP
    J Chromatogr; 1984 May; 290():223-30. PubMed ID: 6736162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-performance liquid chromatographic separation of cadralazine from its potential metabolites and degradation products. Quantitation of the drug in human plasma and urine.
    Crolla T; Santini F; Visconti M; Pifferi G
    J Chromatogr; 1984 Sep; 310(1):139-49. PubMed ID: 6501510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
    Bramer SL; Forbes WP; Mallikaarjun S
    Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute bioavailability of amezinium. A cross-over study after i.v. and p.o. application.
    Kaumeier S; Kehrhahn OH; Morgenthaler H; Neugebauer G
    Arzneimittelforschung; 1981; 31(9a):1653-7. PubMed ID: 7197980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic profile of the antihypertensive vasodilator cadralazine in conscious dogs.
    Dorigotti L; Ferni G; Lombroso M; Semeraro C
    Arzneimittelforschung; 1984; 34(9):984-7. PubMed ID: 6542375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
    Bramer SL; Suri A
    Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.
    Reece PA; Cozamanis I; Zacest R
    Eur J Clin Pharmacol; 1982; 23(6):523-7. PubMed ID: 7160421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cadralazine in hypertensive patients.
    Leonetti G; Parini J; Visconti M; Gradnik R
    Eur J Drug Metab Pharmacokinet; 1988; 13(4):295-300. PubMed ID: 3243325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
    Schulz HU; Schürer M; Bässler D; Weiser D
    Arzneimittelforschung; 2005; 55(10):561-8. PubMed ID: 16294501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of ISF-2405, an active metabolite of cadralazine, in plasma and tissues by radioimmunoassay.
    Terauchi Y; Watari S; Ishikawa S; Nakao M; Negoro T; Kagemoto A; Sekine Y; Hashimoto M
    J Pharmacobiodyn; 1987 Dec; 10(12):758-66. PubMed ID: 3451960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.
    Mallikaarjun S; Forbes WP; Bramer SL
    Clin Pharmacokinet; 1999; 37 Suppl 2():33-40. PubMed ID: 10702885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs.
    Ishizaki T; Chiba K; Suganuma T; Sasaki T; Kamiyama H; Nakano H
    J Pharm Sci; 1984 Apr; 73(4):494-8. PubMed ID: 6233416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.